Pular para o conteúdo
Merck
  • Optimizing the primary particle size distributions of pressurized metered dose inhalers by using inkjet spray drying for targeting desired regions of the lungs.

Optimizing the primary particle size distributions of pressurized metered dose inhalers by using inkjet spray drying for targeting desired regions of the lungs.

Drug development and industrial pharmacy (2013-11-21)
T Ehtezazi, M J Davies, L Seton, M N Morgan, S Ross, G D Martin, I M Hutchings
RESUMO

Conventional suspension pressurized metered dose inhalers (pMDIs) suffer not only from delivering small amounts of a drug to the lungs, but also the inhaled dose scatters all over the lung regions. This results in much less of the desired dose being delivered to regions of the lungs. This study aimed to improve the aerosol performance of suspension pMDIs by producing primary particles with narrow size distributions. Inkjet spray drying was used to produce respirable particles of salbutamol sulfate. The Next Generation Impactor (NGI) was used to determine the aerosol particle size distribution and fine particle fraction (FPF). Furthermore, oropharyngeal models were used with the NGI to compare the aerosol performances of a pMDI with monodisperse primary particles and a conventional pMDI. Monodisperse primary particles in pMDIs showed significantly narrower aerosol particle size distributions than pMDIs containing polydisperse primary particles. Monodisperse pMDIs showed aerosol deposition on a single stage of the NGI as high as 41.75 ± 5.76%, while this was 29.37 ± 6.79% for a polydisperse pMDI. Narrow size distribution was crucial to achieve a high FPF (49.31 ± 8.16%) for primary particles greater than 2 µm. Only small polydisperse primary particles with sizes such as 0.65 ± 0.28 µm achieved a high FPF with (68.94 ± 6.22%) or without (53.95 ± 4.59%) a spacer. Oropharyngeal models also indicated a narrower aerosol particle size distribution for a pMDI containing monodisperse primary particles compared to a conventional pMDI. It is concluded that, pMDIs formulated with monodisperse primary particles show higher FPFs that may target desired regions of the lungs more effectively than polydisperse pMDIs.

MATERIAIS
Número do produto
Marca
Descrição do produto

Sigma-Aldrich
Glicerol, ACS reagent, ≥99.5%
Sigma-Aldrich
Glicerol, for molecular biology, ≥99.0%
Sigma-Aldrich
Glicerol, ReagentPlus®, ≥99.0% (GC)
Sigma-Aldrich
Glicerol, 83.5-89.5% (T)
Sigma-Aldrich
Glicerol, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for electrophoresis, ≥99% (GC)
Sigma-Aldrich
Glicerol, BioUltra, for molecular biology, anhydrous, ≥99.5% (GC)
Sigma-Aldrich
Glicerol, puriss., anhydrous, 99.0-101.0% (alkalimetric)
Sigma-Aldrich
Glicerol, FCC, FG
Sigma-Aldrich
Glicerol, puriss. p.a., ACS reagent, anhydrous, dist., ≥99.5% (GC)
Sigma-Aldrich
Glicerol, ≥99.5%
Sigma-Aldrich
Glicerol, BioXtra, ≥99% (GC)
Sigma-Aldrich
Glicerol, meets USP testing specifications
Supelco
Glicerol, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Glicerol, puriss., meets analytical specification of Ph. Eur., BP, 84-88%
Sigma-Aldrich
Salbutamol hemisulfate salt, ≥98%
Supelco
Glicerol, analytical standard
Supelco
Albuterol sulfate, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Glicerol, tested according to Ph. Eur., anhydrous
Salbutamol sulfate, European Pharmacopoeia (EP) Reference Standard